Table 2.
Selected miRNA | Function related to hyperuricemia/gout | Reference |
---|---|---|
miR-17-5p* | suppresses NLRP3 inflammasome activation, miR-17-92 cluster | [17, 18] |
miR-18a-5p* | increased by IL-1β in OA, miR-17-92 cluster | [19] |
miR-30a-3p | regulates the autoimmune responses occurring in RA | [20] |
miR-30c-5p* | inhibits pyroptosis incurred by NLRP3 | [21] |
miR-126-3p | targets the CCL2 mRNA | [22] |
miR-133a-3p* | suppresses NLRP3 inflammasome activation | [23] |
miR-142-3p* | inhibits the expression of ABCG2 | [24] |
miR-143-3p* | targets the GLUT9 mRNA | [25] |
miR-146a-5p | increased by MSU crystals, regulates the inflammatory response | [26] |
miR-155-5p | increased by MSU crystals, promotes the production of proinflammatory cytokines | [27] |
miR-222-3p* | targets the ABCG2 mRNA | [28] |
miR-223-3p | reduces NLRP3 inflammasome activity | [14] |
miR-488-3p | regulates the production of proinflammatory cytokines, targets the IL1B mRNA, decreased at patients with GA | [29] |
miR-920 | regulates the production of proinflammatory cytokines, targets the IL1B mRNA, decreased at patients with GA | [29] |
OA osteoarthritis, RA rheumatoid arthritis, MSU monosodium urate, GA gouty arthritis
miRNAs signed with a * indicate significant differences in TLDA screening